Patient and disease characteristics for non–MET‐amplified and MET‐amplified patients
| Characteristics . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | p value . |
|---|---|---|---|
| Age, mean ± SD | 59.9 ± 12.2 | 60.6 ± 12.9 | .80 |
| Sex | .81 | ||
| Male | 155 (76.0) | 21 (74.0) | |
| Female | 50 (24.0) | 7 (26.0) | |
| ECOG PS | .60 | ||
| 1 | 107 (52.0) | 13 (44.0) | |
| 2 | 86 (42.0) | 13 (48.0) | |
| 3 | 12 (6.0) | 2 (7.0) | |
| Race | .16 | ||
| White | 170 (83.0) | 22 (77.0) | |
| Asian | 6 (3.0) | 2 (7.0) | |
| Black | 7 (3.0) | 0 | |
| Hispanic/Latino | 2 (1.0) | 2 (7.0) | |
| Other | 10 (5.0) | 1 (3.5) | |
| Unknown | 10 (5.0) | 1 (3.5) | |
| Family history of GI cancer | .07 | ||
| Yes | 35 (17.0) | 9 (32.1) | |
| No | 170 (83.0) | 19 (68.0) | |
| Weight loss, mean ± SD, lb | 8.8 ± 14.6 | 11.9 ± 19.65 | .84 |
| Smoking | .15 | ||
| Current | 21 (10.0) | 5 (18.0) | |
| Past | 87 (42.0) | 15 (52.0) | |
| Nonsmoker | 97 (47.0) | 8 (30.0) | |
| Alcohol | .71 | ||
| Current/heavy | 45 (22.0) | 5 (15.0) | |
| Remote/heavy | 13 (6.0) | 2 (7.0) | |
| Nonalcoholic | 147 (72.0) | 21 (78.0) | |
| Helicobacter pylori | .13 | ||
| Yes | 21 (10.0) | 1 (3.5) | |
| No | 31 (15.0) | 1 (3.5) | |
| Unknown | 153 (74.6) | 26 (92.0) | |
| GERD | .99 | ||
| Yes | 115 (56.0) | 16 (55.0) | |
| No | 90 (43.5) | 12 (44.0) | |
| PPI | .53 | ||
| Yes | 113 (65.0) | 15 (52.0) | |
| No | 92 (44.3) | 13 (48.0) | |
| On blood thinner | .77 | ||
| Yes | 30 (15.0) | 4 (11.0) | |
| No | 175 (85.0) | 24 (89.0) | |
| Dysphagia | .15 | ||
| Yes | 80 (40.5) | 16 (55.5) | |
| No | 122 (59.5) | 12 (44.4) | |
| Anemia | .013 | ||
| No | 115 (56.0) | 23 (81.5) | |
| Yes | 90 (43.4) | 5 (18.5) | |
| Pain at presentation | .99 | ||
| Yes | 99 (48.0) | 13 (48.0) | |
| No | 106 (52.0) | 15 (52.0) | |
| Able to swallow | .33 | ||
| Yes | 155 (76.0) | 24 (85.0) | |
| No | 50 (24.0) | 4 (15.0) | |
| Stage at presentation | .99 | ||
| Locally advanced | 47 (23.0) | 6 (22.0) | |
| Metastatic | 158 (77.0) | 22 (78.0) | |
| Primary tumor | .2 | ||
| Not resected | 18 (38.0) | 4 (67.0) | |
| Resected | 29 (62.0) | 2 (33.0) | |
| Reoccurrence after resection | .99 | ||
| No | 8 (27.0) | 0 | |
| Yes | 21 (72.0) | 2 (100) |
| Characteristics . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | p value . |
|---|---|---|---|
| Age, mean ± SD | 59.9 ± 12.2 | 60.6 ± 12.9 | .80 |
| Sex | .81 | ||
| Male | 155 (76.0) | 21 (74.0) | |
| Female | 50 (24.0) | 7 (26.0) | |
| ECOG PS | .60 | ||
| 1 | 107 (52.0) | 13 (44.0) | |
| 2 | 86 (42.0) | 13 (48.0) | |
| 3 | 12 (6.0) | 2 (7.0) | |
| Race | .16 | ||
| White | 170 (83.0) | 22 (77.0) | |
| Asian | 6 (3.0) | 2 (7.0) | |
| Black | 7 (3.0) | 0 | |
| Hispanic/Latino | 2 (1.0) | 2 (7.0) | |
| Other | 10 (5.0) | 1 (3.5) | |
| Unknown | 10 (5.0) | 1 (3.5) | |
| Family history of GI cancer | .07 | ||
| Yes | 35 (17.0) | 9 (32.1) | |
| No | 170 (83.0) | 19 (68.0) | |
| Weight loss, mean ± SD, lb | 8.8 ± 14.6 | 11.9 ± 19.65 | .84 |
| Smoking | .15 | ||
| Current | 21 (10.0) | 5 (18.0) | |
| Past | 87 (42.0) | 15 (52.0) | |
| Nonsmoker | 97 (47.0) | 8 (30.0) | |
| Alcohol | .71 | ||
| Current/heavy | 45 (22.0) | 5 (15.0) | |
| Remote/heavy | 13 (6.0) | 2 (7.0) | |
| Nonalcoholic | 147 (72.0) | 21 (78.0) | |
| Helicobacter pylori | .13 | ||
| Yes | 21 (10.0) | 1 (3.5) | |
| No | 31 (15.0) | 1 (3.5) | |
| Unknown | 153 (74.6) | 26 (92.0) | |
| GERD | .99 | ||
| Yes | 115 (56.0) | 16 (55.0) | |
| No | 90 (43.5) | 12 (44.0) | |
| PPI | .53 | ||
| Yes | 113 (65.0) | 15 (52.0) | |
| No | 92 (44.3) | 13 (48.0) | |
| On blood thinner | .77 | ||
| Yes | 30 (15.0) | 4 (11.0) | |
| No | 175 (85.0) | 24 (89.0) | |
| Dysphagia | .15 | ||
| Yes | 80 (40.5) | 16 (55.5) | |
| No | 122 (59.5) | 12 (44.4) | |
| Anemia | .013 | ||
| No | 115 (56.0) | 23 (81.5) | |
| Yes | 90 (43.4) | 5 (18.5) | |
| Pain at presentation | .99 | ||
| Yes | 99 (48.0) | 13 (48.0) | |
| No | 106 (52.0) | 15 (52.0) | |
| Able to swallow | .33 | ||
| Yes | 155 (76.0) | 24 (85.0) | |
| No | 50 (24.0) | 4 (15.0) | |
| Stage at presentation | .99 | ||
| Locally advanced | 47 (23.0) | 6 (22.0) | |
| Metastatic | 158 (77.0) | 22 (78.0) | |
| Primary tumor | .2 | ||
| Not resected | 18 (38.0) | 4 (67.0) | |
| Resected | 29 (62.0) | 2 (33.0) | |
| Reoccurrence after resection | .99 | ||
| No | 8 (27.0) | 0 | |
| Yes | 21 (72.0) | 2 (100) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; GERD, gastroesophageal reflux disease, GI, gastrointestinal; MET amp, MET‐amplified; MET non‐amp, non–MET‐amplified; PPI, proton pump inhibitors.
Patient and disease characteristics for non–MET‐amplified and MET‐amplified patients
| Characteristics . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | p value . |
|---|---|---|---|
| Age, mean ± SD | 59.9 ± 12.2 | 60.6 ± 12.9 | .80 |
| Sex | .81 | ||
| Male | 155 (76.0) | 21 (74.0) | |
| Female | 50 (24.0) | 7 (26.0) | |
| ECOG PS | .60 | ||
| 1 | 107 (52.0) | 13 (44.0) | |
| 2 | 86 (42.0) | 13 (48.0) | |
| 3 | 12 (6.0) | 2 (7.0) | |
| Race | .16 | ||
| White | 170 (83.0) | 22 (77.0) | |
| Asian | 6 (3.0) | 2 (7.0) | |
| Black | 7 (3.0) | 0 | |
| Hispanic/Latino | 2 (1.0) | 2 (7.0) | |
| Other | 10 (5.0) | 1 (3.5) | |
| Unknown | 10 (5.0) | 1 (3.5) | |
| Family history of GI cancer | .07 | ||
| Yes | 35 (17.0) | 9 (32.1) | |
| No | 170 (83.0) | 19 (68.0) | |
| Weight loss, mean ± SD, lb | 8.8 ± 14.6 | 11.9 ± 19.65 | .84 |
| Smoking | .15 | ||
| Current | 21 (10.0) | 5 (18.0) | |
| Past | 87 (42.0) | 15 (52.0) | |
| Nonsmoker | 97 (47.0) | 8 (30.0) | |
| Alcohol | .71 | ||
| Current/heavy | 45 (22.0) | 5 (15.0) | |
| Remote/heavy | 13 (6.0) | 2 (7.0) | |
| Nonalcoholic | 147 (72.0) | 21 (78.0) | |
| Helicobacter pylori | .13 | ||
| Yes | 21 (10.0) | 1 (3.5) | |
| No | 31 (15.0) | 1 (3.5) | |
| Unknown | 153 (74.6) | 26 (92.0) | |
| GERD | .99 | ||
| Yes | 115 (56.0) | 16 (55.0) | |
| No | 90 (43.5) | 12 (44.0) | |
| PPI | .53 | ||
| Yes | 113 (65.0) | 15 (52.0) | |
| No | 92 (44.3) | 13 (48.0) | |
| On blood thinner | .77 | ||
| Yes | 30 (15.0) | 4 (11.0) | |
| No | 175 (85.0) | 24 (89.0) | |
| Dysphagia | .15 | ||
| Yes | 80 (40.5) | 16 (55.5) | |
| No | 122 (59.5) | 12 (44.4) | |
| Anemia | .013 | ||
| No | 115 (56.0) | 23 (81.5) | |
| Yes | 90 (43.4) | 5 (18.5) | |
| Pain at presentation | .99 | ||
| Yes | 99 (48.0) | 13 (48.0) | |
| No | 106 (52.0) | 15 (52.0) | |
| Able to swallow | .33 | ||
| Yes | 155 (76.0) | 24 (85.0) | |
| No | 50 (24.0) | 4 (15.0) | |
| Stage at presentation | .99 | ||
| Locally advanced | 47 (23.0) | 6 (22.0) | |
| Metastatic | 158 (77.0) | 22 (78.0) | |
| Primary tumor | .2 | ||
| Not resected | 18 (38.0) | 4 (67.0) | |
| Resected | 29 (62.0) | 2 (33.0) | |
| Reoccurrence after resection | .99 | ||
| No | 8 (27.0) | 0 | |
| Yes | 21 (72.0) | 2 (100) |
| Characteristics . | MET non‐amp (n = 205, 88.0%), n (%) . | MET amp (n = 28, 12.0%), n (%) . | p value . |
|---|---|---|---|
| Age, mean ± SD | 59.9 ± 12.2 | 60.6 ± 12.9 | .80 |
| Sex | .81 | ||
| Male | 155 (76.0) | 21 (74.0) | |
| Female | 50 (24.0) | 7 (26.0) | |
| ECOG PS | .60 | ||
| 1 | 107 (52.0) | 13 (44.0) | |
| 2 | 86 (42.0) | 13 (48.0) | |
| 3 | 12 (6.0) | 2 (7.0) | |
| Race | .16 | ||
| White | 170 (83.0) | 22 (77.0) | |
| Asian | 6 (3.0) | 2 (7.0) | |
| Black | 7 (3.0) | 0 | |
| Hispanic/Latino | 2 (1.0) | 2 (7.0) | |
| Other | 10 (5.0) | 1 (3.5) | |
| Unknown | 10 (5.0) | 1 (3.5) | |
| Family history of GI cancer | .07 | ||
| Yes | 35 (17.0) | 9 (32.1) | |
| No | 170 (83.0) | 19 (68.0) | |
| Weight loss, mean ± SD, lb | 8.8 ± 14.6 | 11.9 ± 19.65 | .84 |
| Smoking | .15 | ||
| Current | 21 (10.0) | 5 (18.0) | |
| Past | 87 (42.0) | 15 (52.0) | |
| Nonsmoker | 97 (47.0) | 8 (30.0) | |
| Alcohol | .71 | ||
| Current/heavy | 45 (22.0) | 5 (15.0) | |
| Remote/heavy | 13 (6.0) | 2 (7.0) | |
| Nonalcoholic | 147 (72.0) | 21 (78.0) | |
| Helicobacter pylori | .13 | ||
| Yes | 21 (10.0) | 1 (3.5) | |
| No | 31 (15.0) | 1 (3.5) | |
| Unknown | 153 (74.6) | 26 (92.0) | |
| GERD | .99 | ||
| Yes | 115 (56.0) | 16 (55.0) | |
| No | 90 (43.5) | 12 (44.0) | |
| PPI | .53 | ||
| Yes | 113 (65.0) | 15 (52.0) | |
| No | 92 (44.3) | 13 (48.0) | |
| On blood thinner | .77 | ||
| Yes | 30 (15.0) | 4 (11.0) | |
| No | 175 (85.0) | 24 (89.0) | |
| Dysphagia | .15 | ||
| Yes | 80 (40.5) | 16 (55.5) | |
| No | 122 (59.5) | 12 (44.4) | |
| Anemia | .013 | ||
| No | 115 (56.0) | 23 (81.5) | |
| Yes | 90 (43.4) | 5 (18.5) | |
| Pain at presentation | .99 | ||
| Yes | 99 (48.0) | 13 (48.0) | |
| No | 106 (52.0) | 15 (52.0) | |
| Able to swallow | .33 | ||
| Yes | 155 (76.0) | 24 (85.0) | |
| No | 50 (24.0) | 4 (15.0) | |
| Stage at presentation | .99 | ||
| Locally advanced | 47 (23.0) | 6 (22.0) | |
| Metastatic | 158 (77.0) | 22 (78.0) | |
| Primary tumor | .2 | ||
| Not resected | 18 (38.0) | 4 (67.0) | |
| Resected | 29 (62.0) | 2 (33.0) | |
| Reoccurrence after resection | .99 | ||
| No | 8 (27.0) | 0 | |
| Yes | 21 (72.0) | 2 (100) |
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; GERD, gastroesophageal reflux disease, GI, gastrointestinal; MET amp, MET‐amplified; MET non‐amp, non–MET‐amplified; PPI, proton pump inhibitors.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
